Crystalline forms and formulations of a kras inhibitor

Abstract

The present disclosure relates to crystalline forms of 2-Amino-7-fluoro-4-(5-fluoro-3-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-1-((1R,5S)-3-((R)-2-hydroxypropyl)-3,8-diazabicyclo[3.2.1]octan-8-yl)-7,9-dihydrofuro[3,4-f]quinazolin-6-yl)thieno[3,2-c]pyridine-3-carbonitrile and pharmaceutical formulations comprising the compound or a pharmaceutically acceptable salt thereof, methods of making, and use for the treatment of disease.

Dependencies are inferred from the claim text.